Quick Answer
INTEGRATED BIOPHARMA INC reported Cash and Equivalents of $3.62 million for fiscal year 2025.
INTEGRATED BIOPHARMA INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.62M | +115.6% |
| 2024 | $1.68M | +27.4% |
| 2023 | $1.32M | +297.6% |
| 2022 | $331.0K | +57.6% |
| 2021 | $210.0K | -47.8% |
| 2020 | $402.0K | -15.4% |
| 2019 | $475.0K | +108.3% |
| 2018 | $228.0K | +72.7% |
| 2017 | $132.0K | -66.6% |
| 2016 | $395.0K | +456.3% |
| 2015 | $71.0K | -84.3% |
| 2014 | $451.0K | +720.0% |
| 2013 | $55.0K | -62.1% |
| 2012 | $145.0K | -80.0% |
| 2011 | $725.0K | +12.1% |
| 2010 | $647.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $5.31M | +115.9% | +12.3% |
| September 30, 2025 | $4.73M | +108.4% | +30.9% |
| June 30, 2025 | $3.62M | +115.6% | +22.1% |
| March 31, 2025 | $2.96M | +46.6% | +20.3% |
| December 31, 2024 | $2.46M | +236.2% | +8.4% |
| September 30, 2024 | $2.27M | -12.5% | +35.4% |
| June 30, 2024 | $1.68M | +27.4% | -17.0% |
| March 31, 2024 | $2.02M | -20.1% | +176.0% |
- INTEGRATED BIOPHARMA INC showed an increase of +115.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, INTEGRATED BIOPHARMA INC’s cash and equivalents has grown by 458.7% (from $647.0 thousand to $3.62 million).
- The most recent figure is from INTEGRATED BIOPHARMA INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: